Polyneuron
OverviewSuggest Edit
Polyneuron is a pharmaceutical company that is committed to the development of a new drug class for the treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. The Company’s Antibody-Catch™ technology platform enables the chemical design of injectable glycopolymers that are able to selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact.
| Type | Private | |
| Founded | 2014 | |
| HQ | Basel, CH | Map |
| Website | polyneuron.com |
Recent NewsAll News
- Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants
- Polyneuron appoints Aled Williams as chief business officer
- Polyneuron extends Series A to CHF 36.5 million
- Polyneuron’s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy
Latest Updates
| Employees (est.) (Jul 2021) | 17 | (+7%) |
| Cybersecurity rating | B | More |
Key People/Management at Polyneuron
Ruben Herrendorff
Barker M.D.
Pascal Haenggi
Aled Williams
Pascal Hänggi
Polyneuron Office Locations
Polyneuron Financials and Metrics
Summary Metrics
Founding Date | 2014 |
Polyneuron total Funding | $44.3 m |
Polyneuron latest funding size | $15.33 m |
Time since last funding | 10 months ago |
Polyneuron investors | New Enterprise Associates, Sofinnova Partners, EVA Basel, Zürcher Kantonal Bank, HBM Healthcare Investments, Venture Kick |
Polyneuron Cybersecurity Score
Polyneuron Online and Social Media Presence
253 Twitter followers
Polyneuron has 253 Twitter Followers. The number of followers has decreased 1.5% month over month and decreased 1.2% quarter over quarter
Polyneuron's Trends
Polyneuron Blogs
Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplants
Polyneuron appoints Aled Williams as chief business officer
Polyneuron extends Series A to CHF 36.5 million
Polyneuron’s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy
Polyneuron announces appointment of chief medical officer
Polyneuron Frequently Asked Questions
When was Polyneuron founded?
Polyneuron was founded in 2014.
Who are Polyneuron key executives?
Polyneuron's key executives are Ruben Herrendorff, Barker M.D. and Pascal Haenggi.
How many employees does Polyneuron have?
Polyneuron has 17 employees.
Who are Polyneuron competitors?
Competitors of Polyneuron include ReViral, Sosei Heptares and Seres Therapeutics.
Where is Polyneuron headquarters?
Polyneuron headquarters is located at Hochbergerstrasse 60C, Basel.
Where are Polyneuron offices?
Polyneuron has an office in Basel.
How many offices does Polyneuron have?
Polyneuron has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies